Halterbio

Small clinical-stage and commercial life-sciences teams may need to watch multiple public and licensed safety sources without operating a large enterprise platform. Statistical thresholds can help surface unusual drug-event combinations, but a crossing is not a validated safety signal, an adverse-event case, a causal relationship or a reporting decision.

Halterbio runs sponsor-approved queries against configured sources and records the dataset version, portfolio scope, method, parameters, result and supporting citations. It deduplicates repeated observations and routes candidates to a qualified pharmacovigilance reviewer. Messaging channels receive only a minimal notice and link; sensitive case details stay in the controlled workspace.

Reviewer triage, signal validation, medical assessment, case processing, reportability determination, regulatory submission authority, provider acknowledgment and authority acceptance remain distinct. An append-only evidence history shows what the system observed and how the record changed. Integrity evidence does not establish truth, completeness or compliance.

The product prepares a bounded review queue and line listing. It does not satisfy reporting obligations by itself, calculate causality, replace source-system case intake, suppress alerts autonomously or submit anything without named authority.

Pharmacovigilance, drug-safety or regulatory operations leader at a clinical-stage biotechnology company or small pharmaceutical sponsor